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Abstract: Non-alcoholic steatohepatitis (NASH) is a major cause of chronic liver disease. However,
most available animal models fail to reflect the whole spectrum of the disease. Liver fibrosis and
portal hypertension are the strongest prognostic markers in advanced NASH. We herein aimed at
developing a new model of NASH in male rats, obtained using a multi-hit protocol that combines
the administration of a high fat and high-cholesterol diet with CCl4 and phenobarbital. Following
this protocol, rats showed the full characteristics of advanced human NASH after 10 weeks and
NASH with cirrhosis by 24 weeks. Specifically, our NASH rats exhibited: steatosis and metabolic
syndrome, lipotoxicity, hepatocellular ballooning necrosis, inflammation and importantly, marked
hepatic fibrosis and significant portal hypertension. Furthermore, a whole transcriptomic analysis of
liver tissue from our rat model using next generation sequencing was compared with human NASH
and illustrated the similarity of this pre-clinical model with the human disease. Pathway enrichment
analysis showed that NASH animals shared a relevant number of central pathways involved in
NASH pathophysiology, such as those related with cell death, as well as inflammatory or matrix
remodeling. The present study defines a pre-clinical model of moderate and advanced NASH that
mimics the human disease, including pathophysiologic characteristics and transcriptomic signature.
Keywords: steatosis; cirrhosis; hepatic fibrosis; portal hypertension; steatohepatitis
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is considered a new epidemy in chronic liver diseases.
In fact, its prevalence has been estimated to be as high as 25% in the general population and even higher
(>70%) in patients with other metabolic risk factors like obesity and diabetes [1,2]. Additionally, it is
well known than up to 30% of the NAFLD population will further progress and develop non-alcoholic
steatohepatitis (NASH), the more severe form of fatty liver disease. NASH can progress to the
end-stages of chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC) [3].
In view of the increasing incidence of NAFLD worldwide, a large number of translational
laboratories are focused on understanding new aspects of NASH pathophysiology, on discovering
specific and non-invasive diagnostic biomarkers, and developing effective pharmacologic treatments [4].
Nevertheless, the lack of reliable NASH animal models remains a limitation for studying the disease and
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for developing new therapeutic strategies [5]. Currently available animal models include genetic (Ob/Ob
and Db/Db), dietary (high-fat diets [6] and methionine choline-deficient diet [7]) or a combination of
both [8]. The major disadvantage of most of these models is that they fail to reflect advanced human
disease. In this regard, it is important to denote that liver fibrosis represents the strongest predictor
for NAFLD-specific mortality, [9] and portal hypertension is present in 25% of patients at the time of
diagnosis of NASH [10]. Therefore, it is necessary to consider these pathological features to properly
study NASH. Surprisingly, and despite its current relevance worldwide, no pre-clinical model of
NASH with significant fibrosis and portal hypertension, together with the other relevant characteristics
of the disease, has been well characterized so far [11].
Carbon tetrachloride (CCl4) has been widely used for decades to induce liver injury and fibrosis
in murine models. Previous reports suggested that the use of CCl4, in combination with a high-fat diet,
induced liver injury and some features of NASH at short-term [12], and HCC development at long
term exposure [13]. However, these studies were developed in mice, which represents a limitation
for proper hepatic hemodynamic evaluation and liver cells’ isolation. Indeed, a rat model would
be preferable, because the size of the animal facilitates monitoring physiological parameters and the
purification of high yields of parenchymal and non-parenchymal liver cells, and moreover, because rat
models have been postulated to better correspond with human diseases [14].
Considering this background, we herein aimed at developing a new model of NASH in rats
obtained using a multi-hit protocol that combines the administration of a high-fat and high-cholesterol
diet with CCl4 + phenobarbital. Following this protocol, rats reflect the full features of advanced
human NASH after 10 weeks of administration and NASH with cirrhosis by 24 weeks. We further
demonstrate that this new model shares relevant pathophysiological pathways with human NASH
using next generation sequencing and pathway enrichment analysis.
2. Materials and Methods
2.1. Animal Model
Male Wistar rats underwent a multi-hit liver injury protocol (termed Barcelona NASH [BarNa]
model) that combines a high-fat (46.1%) and high-cholesterol (197 ppm) diet (HFCD) (Testdiet, St. Louis,
MO, United States) with CCl4 inhalation (Sigma, Fluka, 87031) and oral phenobarbital added to the
drinking water, as described previously [15]. We designed a protocol to achieve NASH after 10 weeks
of intervention (NASH group) and a protocol to obtain NASH with established cirrhosis (NASH-CH
group) after 24 weeks. In the NASH model, rats were exposed to 6 weeks of CCl4 inhalation and oral
phenobarbital, followed by 4 weeks of HFCD. To obtain the NASH-CH model, rats were exposed to 8
weeks of CCl4 inhalation and oral phenobarbital, followed by 16 weeks of HFCD, CCl4 inhalation, and
oral phenobarbital. Control rats were fed a standard chow diet (13% fat) (Envigo, Huntingdon, United
Kingdom), with normal water for 12 weeks. N = 6 animals were included in each experimental group.
Rats were housed (2 per cage) in a 12 h light–12 h dark cycle and were fed ad libitum. Animals were
kept in environmentally-controlled animal facilities. All procedures were approved by the Laboratory
Animal Care and Use Committee of the University of Barcelona and were conducted in accordance with
the European Economic Community guidelines for the protection of animals used for experimental
and other scientific purposes (EEC Directive 86/609).
2.2. Glucose Tolerance Test (GTT)
Rats were fasted for 5 h before the administration of a glucose bolus (2 mg/g, i.p.; Braun Medical,
Rubí, Spain). Glycemia was determined at 0, 15, 30, 60, 90, and 120 min after glucose administration
with the AccuCheck glucose sensor (Roche Diagnostics, Sant Cugat del Valles, Spain). GTT was
performed 5 days before the hemodynamic studies [16].
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2.3. In Vivo Hemodynamic Analysis
Rats were anesthetized with ketamine (100 mg/kg body weight, Imalgene 1000; Merial) plus
midazolam (5 mg/kg body weight; Laboratorio Reig Jofre, S.A., Spain) intraperitoneally, fastened to a
surgical board, and maintained at a constant temperature of 37 ± 0.5 ◦C.
A tracheotomy and cannulation with a PE-240 catheter (Portex, Ashford, UK) was performed
in order to maintain adequate respiration during anesthesia. Indwelling catheters made of PE-50
polyethylene tubing (Portex, Ashford, UK) were placed into the femoral artery to measure mean
arterial pressure (MAP; mmHg) and heart rate (HR; beats per minute), and to the ileocolic vein to
measure portal pressure (PP; mmHg) [17,18]. Portal blood flow (PBF; mL/min) was measured with
a non-constrictive perivascular ultrasonic transit-time flow probe (2PR, 2-mm diameter; Transonic
Systems Inc., USA), placed around the portal vein just before its entrance in the liver, avoiding the
measurement of portal-collateral blood flow. The flow probe and pressure transducers were connected
to a Powerlab (4SP) linked to a computer using Chart v5.5.6 for Windows software (AD Instruments,
Bella Vista, Australia). Hepatic vascular resistance (HVR) was calculated as PP / PBF. Hemodynamic
data were collected after a 20-min stabilization period. Bile was collected during the stabilization
period by cannulation of the bile duct with a PE-10 catheter (Portex, Ashford, UK) and expressed as
bile volume (µL)/time of bile collection (min). At the end of the in vivo hemodynamic study, blood
samples were collected to subsequently evaluate biochemical measurements [19]. Hemodynamic
studies were performed as an end-point of the experiment after 10 weeks in the NASH group, 12 weeks
in the control group, and 24 weeks in the NASH-CH group.
2.4. Biochemical Measurements
Liver transaminases, bilirubin, triglycerides, total cholesterol, low density lipoprotein-cholesterol
(LDL), high density lipoprotein-cholesterol (HDL), and free fatty acids (FFA) were analyzed in plasma
with standard methods at the hospital clinic’s CORE lab [20].
Hepatic lipid peroxidation was determined by measuring the formation of malondialdehyde
(MDA) with the thiobarbiturate reaction [19].
Non-fasting plasma insulin was measured with the ultrasensitive rat insulin ELISA kit (90060,
Crystal Chem, Zaandam, Netherlands), according to the manufacturer’s instructions.
2.5. Liver Histology
Liver samples were fixed in 10% formalin, embedded in paraffin, sectioned, and slides were
stained with hematoxylin and eosin (H&E) for assessment of liver histology, and with Sirius Red
for liver fibrosis evaluation. Fibrosis was evaluated as the collagen proportional area (percent of
red-stained area out of total area of the liver section) using ImageJ software. NAFLD activity score and
fibrosis stage were evaluated by an expert pathologist according to the NASH clinical research network
(CRN) scoring system. The histological scoring was performed without knowing the rat group and
protocol [21,22].
2.6. Oil Red O Staining
Liver samples were frozen in OCT, sectioned, and slides were stained with Oil red O (Sigma
Aldrich, San Luis, MO, USA) for lipid analysis. Lipid droplets were evaluated as the red-stained area
per total area using the ImageJ software [20].
2.7. Cell Death
Terminal deoxynucleotidyl transferase dUTP (2′-Deoxyuridine, 5′-Triphosphate) nick end-labeling
(TUNEL) was performed in deparaffinized liver sections using an in situ cell death detection kit (Roche
Diagnostics, Sant Cugat del Valles, Barcelona, Spain) according to the manufacturer’s instructions [18].
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2.8. Immunohistochemistry
Liver samples were fixed in 10% formalin, embedded in paraffin, sectioned and processed for
immunohistochemistry (IHC) or immunofluorescence (IF) as previously described [23]. For IHC, liver
sections were incubated with antibodies against CD32b (sc-13271, Santa Cruz, CA, USA), von Willebrand
factor (VWF) (A0082, Dako, Santa Clara, CA, USA), Desmin (M0760, Dako, Santa Clara, CA, USA),
or CD163 (MCA342R, Biorad, Hercules, CA, USA). After incubation with corresponding secondary
antibodies, color development was induced by incubation with a DAB ((3,3′-diaminobenzidine) kit
(Dako, Santa Clara, CA, USA) and counterstained with hematoxylin. Sections were dehydrated and
mounted. The specific staining was visualized and fifteen images per liver were acquired using a
microscope equipped with a digital camera and the assistance of Axiovision software. The relative
volume was calculated by dividing the number of points positive in sinusoidal areas by the total
number of points over liver tissue (CD32b, vWF, and Desmin). Positive cells per field were quantified
for CD163.
For IF, liver sections were incubated with antibodies against CD68 (MCA341R, Biorad, Hercules,
CA, USA), myeloperoxidase (MPO) (ab9535, Abcam, Cambridge, UK), and histone H2B (ab52484,
Abcam, Cambridge, UK) incubated with secondary antibodies Alexa Fluor 488 or 555 (1:400, Life
technologies) and 4′,6-diamino-2-fenilindol (DAPI) (1:3000, Sigma-Aldrich, San Luis, MO, USA) and
mounted in fluoromount G medium. Ten images per sample were obtained with a fluorescence
microscope and positive cells per field (CD68, MPO) were quantified. Neutrophils activity was
characterized as presence of neutrophil extracellular traps (NETs) (structures double-positive for
myeloperoxidase and histone 2B) [24].
2.9. Western Blotting
Liver samples were processed, and Western blot performed as described [25]. The primary
antibodies used were 3-Nitrotyrosine (N5538, Sigma Aldrich, San Luis, MO, USA), cleaved caspase-3
(9661, Cell Signalling, Danvers, MA, USA), alpha smooth muscle actin (α-SMA) (A2547, Sigma Aldrich,
San Luis, MO, USA), collagen 1α1 (84336, Cell Signalling, Danvers, MA, USA), cellular retinol binding
protein (CRBP1) (sc-271208, Santa Cruz), phosphorylated moesin at Thr558 (sc-12895, Santa Cruz, CA,
USA), total moesin (sc-13122, Santa Cruz, CA, USA), phosphorylated endothelial nitric oxide synthase
(eNOS) at Ser1177 (9571, Cell Signaling, Danvers, MA, USA), and total eNOS (610297, BD Transduction
Laboratories, San Jose, CA, USA), all 1:200. Blots were revealed by chemiluminescence and protein
expression was determined by densitometric analysis using the Image Studio Lite (LI-COR, Lincoln,
USA). Blots were also assayed for α-tubulin (1:1000, Sigma-Aldrich, San Luis, MO, USA) content as
standardization of sample loading.
2.10. Transcriptome Profiling
Global transcriptome profiling of rat liver tissue (n = 6 control, n = 6 NASH, and n = 6 NASH-CH)
was performed by RNA-Seq. Briefly, 20 mg of liver tissue were weighted, and RNA was isolated using
the miRNeasy mini kit (217004, Qiagen, Hilden, Germany) following the manufacturer’s instructions.
The sequencing library was prepared using 1000 ng of total RNA by a TruSeq library prep kit (Illumina,
San Diego, CA, USA) following the manufacturer’s protocol, and resulting data were pre-processed
by our custom pre-processing pipeline. Briefly, after adapter trimming, raw sequencing reads were
aligned against Rattus Norvergicus genome (Rnor_6.0) by Spliced Transcripts Alignment to a Reference
(STAR) [26] 2-pass algorithm, and the quantification of genes and transcripts was done with the
RSEM program [27] using ensembl release 95 [28]. We used the trimmed mean of M values (TMM)
method and limma-voom transformation from rounded expected counts to normalize non-biological
variability. An assessment of differential expression between groups was evaluated using moderated
t-statistics [29]. The dataset is available at the National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus database, accession number GSE129525.
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2.11. Bioinformatic Data Analysis
Human NASH liver transcriptome datasets were used from the GSE48452 database to identify the
commonly dysregulated gene sets between human NASH and rat NASH models. See Supplementary
Table S2 for patients’ clinical characteristic details: patients with NASH (n = 17), steatotic patients
(n = 9) vs. healthy individuals (n = 12). Molecular pathway dysregulations in the rat and human liver
tissues were determined by gene set enrichment analysis by means of pre-ranked Gene Set Enrichment
Analysis (GSEA), in previously transformed human orthologs with the Mouse Genome Informatics
(MGI) database, using the Molecular Signatures Database (MSigDB) database [30] defined as false
discovery rate (FDR) <0.1.
2.12. Statistical Analysis
Statistical analysis was performed with the Prism 7 for Windows (GraphPad Software, San Diego,
California, USA). All results are expressed as mean ± standard error of the mean (SEM). Results were
compared by one-way ANOVA with Tukey post hoc test. Differences were considered significant at a p
values of <0.05.
3. Results
3.1. BarNa Rats Develop Obesity, Liver Disfunction, and Insulin Resistance
In comparison to control animals, NASH (10 weeks) and NASH-CH rats (24 weeks) showed
significant body weight gain (Figure 1A), as well as an increase in liver and epididymal, abdominal,
and mesenteric white adipose tissue weights (Figure 1B). Total cholesterol and LDL-cholesterol were
significantly elevated in plasma from NASH-CH animals (Figure 1C), while no statistical differences were
observed in the NASH group. Additionally, both models of NASH exhibited a reduction in bile production,
suggesting a deterioration in hepatic functionality in comparison to control rats (Figure 1D). Plasma levels
of triglycerides, HDL, FFA, and bilirubin were not altered in both groups of NASH rats (Figure 1 and
Figure S1A–C). Finally, both groups of NASH animals had fasting hyperinsulinemia accompanied by an
abnormal glucose tolerance test response (Figure 1E,F), features associated with insulin resistance.
Figure 1. Metabolic profile of control and NASH rats. (A) Body weight, (B) liver weight, epididymal,
abdominal, and mesenteric white adipose tissue weights, (C) plasma cholesterol, LDL, and triglycerides,
(D) bile production, (E) plasma insulin levels, and (F) glucose tolerance tests were measured in control,
NASH, and NASH-CH rats. Results represent mean ± SEM, * p < 0.05 vs. control group, # p < 0.05 vs.
NASH group (n = 6 rats per group).
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3.2. BarNa Rats Present Liver Histology Features Distinctive of Human NASH
All rats were ranked for each of the four histological features encompassed in human NASH
(steatosis, hepatocyte ballooning, lobular inflammation, and liver fibrosis), according to the CRN Score
System criteria. When compared to the control group, the NASH and NASH-CH groups exhibited
a clear major scoring in all categories resulting in a final score superior to the threshold for NASH
diagnosis (scores of 8 and 9, respectively) (Figure 2A,B).
Figure 2. Liver histology of control and NASH rats. (A) Histopathological images from control, NASH,
and NASH-CH livers. Hematoxylin and eosin (H&E) staining (top row; scale bar = 100 µm), oil red O
staining (second row; scale bar = 200 µm) and Sirius red staining (bottom row; scale bar = 500 µm).
(B) NAS-Score quantification. (C) Oil red O quantification. (D) Sirius red quantification. Results
represent mean ± SEM, * p < 0.05 vs. control group, # p < 0.05 vs. NASH group (n = 6 rats per group).
Oil red evaluation revealed a significant increase in hepatic lipid deposition in NASH (30 ± 4%)
and NASH-CH (43 ± 11%) rats in comparison to control animals (<1%) (Figure 2C). Furthermore,
hepatic fibrosis was elevated in both NASH rats (6 ± 0.5%) and NASH-CH (15 ± 4%) compared to
control rats (<1%) (Figure 2D).
3.3. BarNa Rats Show Elevated Oxidative Stress Levels, Cell Death, and Inflammation
Rats from both BarNa models showed a significant increase in hepatic MDA levels, suggesting
oxidative stress secondary to lipid peroxidation (Figure 3A). Accordingly, hepatic nitrotyrosinated
proteins, marker of peroxynitrite anion formation, were elevated in NASH and NASH-CH rats
compared to the control group, (Figure 3B), altogether supporting elevated oxidative stress levels in
the BarNa models.
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Figure 3. Oxidative stress, cell death, and inflammatory markers in control and NASH animals.
(A) MDA levels in liver tissue. (B) Representative western blot of 3-nitrotyrosine proteins normalized
to α-tubulin and quantification. (C) Left, representative western blot of cleaved caspase-3 protein
normalized to α-tubulin and quantification. Right, representative images of TUNEL staining in liver
tissue and quantification. (D) Plasma transaminases (AST and ALT). (E) Representative images of
neutrophil immunofluorescence in liver tissue (MPO in green, histone 2B in red, nuclei in blue). Left,
neutrophil infiltration measured as MPO positive cells. Right, analysis of hepatic neutrophil extracellular
traps (NETs) determined as co-localization of MPO and histone 2B. (F) Left, representative images of
CD68 immunofluorescence in liver tissue and quantification. Right, representative images of CD163
immunohistochemistry in liver tissue and its quantification. Results represent mean ± SEM, * p < 0.05
vs. control group, # p < 0.05 vs. NASH group (n = 6 rats per group). All images scale bar = 100 µm.
Hepatic cell death evaluation revealed significant increases in cleaved caspase-3 protein expression
and TUNEL quantification in both groups of BarNa rats (Figure 3C), accompanied with elevated
plasma transaminases in the NASH-CH group (Figure 3D).
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NASH-CH rats presented an increase in the number of infiltrated neutrophils and in their activity
(Figure 3E), together with more hepatic CD68 and CD163-positive macrophages in comparison to
the control rats (Figure 3F). The NASH group had numerically higher levels of these inflammatory
parameters, but they did not reach statistical significance.
3.4. BarNa Model Promotes the Activation and Proliferation of HSCs
BarNa rats exhibited an increase in the number of activated hepatic stellate cells (HSCs)
demonstrated by the increase in desmin-positive cells and overexpression of α-SMA protein in
the NASH-CH rats (Figure 4A,B). Accordingly, collagen-1α1 protein was augmented in the NASH-CH
group, but not in NASH rats (Figure 4C). The expression of the chaperon CRBP1 was augmented
in the NASH-CH group, suggesting a major deposition of vitamin A in these animals (Figure 4D).
Additionally, HSCs from NASH-CH animals exhibited a pro-contractile phenotype as demonstrated
by the increased levels of phosphorylated (active) moesin protein (Figure 4E).
Figure 4. HSC phenotype in control and NASH rats. (A) Representative images of desmin
immunohistochemistry in liver tissue and its quantification. (B) α-SMA protein expression in total liver
tissue, normalized to α-tubulin, and corresponding quantification. (C) Collagen-1α1 protein expression in
total liver tissue, normalized to α-tubulin. (D) CRBP1 protein expression in total liver tissue, normalized to
α-tubulin. (E) p-moesin and moesin protein expression in total liver tissue, normalized to α-tubulin. Results
represent mean ± SEM, * p < 0.05 vs. control group, # p < 0.05 vs. NASH group (n = 6 rats per group). All
images scale bar = 100 µm.
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3.5. BarNa Rats Exhibit Hepatic Endothelial Dysfunction
Analysis of liver sinusoidal endothelial cells (LSECs) phenotype markers in NASH and NASH-CH
rats suggested de-differentiation of the hepatic endothelium in comparison to the control group.
NASH and NASH-CH livers exhibited reduced expression of CD32b (Figure 5A), a well-described
marker of LSECs’ differentiation, as well as a remarkable increase in the sinusoidal expression of the
well-established capillarization marker called the von Willebrand Factor (vWF) (Figure 5B). Moreover,
LSECs from NASH and NASH-CH animals exhibited a reduction in their vasodilatory capacity as
illustrated by the reduction in the active phosphorylated form of the endothelial nitric oxide synthase
(eNOS) (Figure 5C).
Figure 5. LSEC phenotype in control and NASH rats. (A) Representative images of CD32b
immunohistochemistry in liver tissue and its quantification. (B) Representative images of vWF
immunohistochemistry in liver tissue and its quantification. (C) p-eNOS and eNOS protein expression
in total liver tissue, normalized to α-tubulin. Results represent mean ± SEM, * p < 0.05 vs. control
group, # p < 0.05 vs. NASH group (n = 6 rats per group). All images scale bar = 100 µm.
3.6. BarNa Rats Show Significant Portal Hypertension
Rats from NASH and NASH-CH groups had significantly higher PP (+38% and +51%, respectively)
in comparison to control animals (Table 1). The presence of portal hypertension in these animals
was a consequence of a significant increase in the hepatic vascular resistance, with no evidence of
hyperdynamic syndrome or presence of ascites. Systemic hemodynamic parameters showed no
significant differences between groups.
Table 1. Hemodynamic characteristics in control and NASH rats.
Control NASH p-Value vs. Control NASH-CH p-Value vs. Control
PP (mmHg) 8.77 ± 0.48 12.14 ± 0.85 <0.01 13.26 ± 0.82 <0.001
HVR (mmHg × min/mL × g) 5.14 ± 0.79 13.14 ± 2.77 <0.05 12.77 ± 2.38 <0.05
PBF (mL/min × g) 1.9 ± 0.25 1.24 ± 0.25 >0.2 1.19 ± 0.22 >0.2
MAP (mmHg) 110→6 110→7 >0.2 112 ± 10 >0.2
HR (BPM) 382 ± 16 365 ± 17 >0.2 347 ± 19 >0.2
Data expressed as mean ± SEM. (n = 6 rats per group). PP: portal pressure; HVR: hepatic vascular resistance; PBF:
portal blood flow; MAP: mean arterial pressure; HR: heart rate.
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3.7. BarNa Rats Share De-Regulations in Main Pathways Involved in Human NAFLD and
NASH Pathophysiology
Whole hepatic gene expression analysis identified 386 and 1,201 genes differentially expressed
comparing NASH and NASH-CH rats with control animals at FDR <0.05 (Figure S2), respectively.
Comparative transcriptomic analysis illustrated that BarNa rats share de-regulations in a significant
part of pathways involved in human NAFLD and NASH pathophysiology. Pathway enrichment
analysis for genes that were commonly up-regulated between NASH, NASH-CH, and human NASH
showed that 29 gene sets including phosphoinositide 3-kinase (PI3K), interleukin 7 (IL7), cell death
signaling, and platelet-derived growth factor (PDGF) were among the most significant dysregulated
pathways (Figure 6A). 54 gene sets were commonly down-regulated between the two rat models and
NASH patients and included: cell cycle regulation, metabolism of RNA, amino acids and proteins,
mitochondrial regulation, and the respiratory electron cycle (Figure 6B). When comparing pathways
commonly up-regulated between NASH, NASH-CH, and steatotic patients, we observed 24 gene
sets significantly altered: cell death signaling pathways, coagulation, notch pathways, and basement
membranes (Figure S3A). 66 gene sets were down-regulated among NASH, NASH-CH, and human
steatosis including: several metabolism pathways, the cell cycle, p53 DNA damage response, and
telomere maintenance (Figure S3B). Interestingly, the NASH-CH BarNa model shared more pathways
with human NASH than with human steatosis, and on the contrary, the NASH BarNa model seemed
to be more coincident with the dysregulated pathways in patients with steatosis.
Figure 6. De-regulation of signaling pathways relevant for human NASH in livers from BarNa
animals. (A) Commonly up-regulated gene sets between human NASH and BarNa rats. (B) Commonly
down-regulated gene sets between human NASH and BarNa rats. Results represent de-regulated
pathways with FDR < 0.1 in a Venn diagram. n = 6 animals per group; n = 12 control human livers, and
n = 17 human NASH livers. Clinical characteristics of donors are described in Table S2.
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4. Discussion
Nowadays, finding a reliable animal model of NASH to better understand the pathophysiology
of the disease, to identify novel biomarkers and to find new targets for therapy, is still a scientific
challenge. An ideal NASH animal model should mimic the full spectrum of the human disease [4].
In this regard, in the present study, we develop and characterize a new male-rat model of NASH
that exhibits the major clinical characteristics of the human pathology: metabolic syndrome, hepatic
steatosis, lipotoxicity, hepatic cell death, hepatic inflammation, hepatic fibrosis, and portal hypertension.
Importantly, the protocol herein described is easy, affordable, and achievable in a relatively short
period of time.
One important characteristic of the human disease, and absent in the most advanced NASH
animal models, is the presence of obesity and metabolic syndrome [5]. Animals under the BarNa
protocol presented evidence of obesity, as suggested by the body and liver weight gain and the
increments in white adipose tissues. Cholesterol and LDL-cholesterol were only elevated in the most
advanced model, NASH-CH, probably because these rats were fed for a longer period with the HFCD
than the NASH group, which indeed agrees with the concept of Wistar rats’ resistance to developing
steatohepatitis, even after long periods of time fed with a fatty diet [6]. Interestingly, BarNa rats showed
insulin resistance and a moderate increase in arterial pressure, two important features associated with
metabolic syndrome [31].
CCl4 is well-known for being a fibrogenic molecule, especially when given in combination with
phenobarbital [32], which is the reason why it has been commonly used for developing animal models
of liver fibrosis and cirrhosis. In our model, both groups of animals following the BarNa protocol
presented significant liver fibrosis: F2–3 stage in the NASH rats and F3–4 in the NASH-CH rats. This
F2–4 profile observed in our BarNa model is also present in the patients with worst prognosis [9,33],
making the BarNa model attractive for studying NASH pathophysiology and anti-fibrotic therapies in
advanced stages of the disease.
BarNa rats showed elevated levels of markers related with oxidative stress, cell death, and
inflammation, which goes along with the natural history of NASH disease [3]. However, transaminases
levels were not significantly altered in our model. Considering that AST/ALT are parameters that
present high variability intra-group [13,19], we hypothesized that our sample size might not be enough
to observe differences.
Activated HSCs are well known to be the cells driving fibrosis development in chronic liver
disease, including NASH [34]. The NASH-CH animals present clear evidence of HSC activation and
proliferation, and therefore explain the fibrotic content observed in this model. Contrarily, and although
NASH animals also presented a significant increment in intrahepatic fibrosis, HSC activation markers
appear to be unaltered in comparison to control animals. This discrepancy may be explained by a
possible spontaneous amelioration in the HSC phenotype once CCl4 was discontinued and animals
only received dietary intervention. Therefore, the 10-week BarNa model should be considered as
a moderately advanced NASH model and could be more appropriate for studying early stages of
NASH disease, while the NASH-CH BarNa model could be used for evaluating advanced fibrosis and
compensated cirrhotic stages of NASH human disease.
Liver diseases, in particular those leading to fibrosis and cirrhosis, are associated with impaired
vitamin A homeostasis, which may lead to vitamin A deficiency [35]. Moreover, loss of vitamin A has
also been defined as a characteristic of activated HSC [36]. In NAFLD, it is not clear whether there exists
a deficiency in vitamin A and/or a disturbance in its metabolism [37]. Some reports analyzing retinoid
metabolism-related genes, like CRBP1, have observed an hyperdynamic state of retinoids pathway in
livers from NAFLD patients [38], while others studies suggest a protective role of vitamin A in NAFLD
progression [39]. Also, there is controversy regarding the contribution of stored retinoids to HSC
activation [34]. In our NASH model, rats presented an inclination to higher stored levels of vitamin A.
Further studies are required to fully understand the role of vitamin A in NAFLD pathophysiology.
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Previous studies have demonstrated that endothelial dysfunction occurs during simple steatosis
development [40] and therefore precedes the development of fibrosis and inflammation [16]. In our
BarNa models, we have observed evidence of liver endothelial injury, as suggested by the expression
of capillarization markers and the depletion of the vasodilatory capacity, features also recognized in
the human disease [41].
Another key feature of the BarNa model, which most probably derives from the above-described
pathologic events, is the presence of significant portal hypertension. This observation is relevant, since
portal hypertension has been detected in almost 30% of the patients with NASH and importantly,
correlates with the hepatic fibrosis stage [10,42,43]. It is well recognized that pre-clinical models of
chronic liver disease do not fully mimic the broad spectrum of the human disease, and the BarNa
model has limitations when compared to human NASH. Nevertheless, the presence of hepatic fibrosis
and portal hypertension, together with the other important features of NASH described above, is a
major strength of this pre-clinical model, since most of the currently available NASH models do not
include these clinically-relevant characteristics.
In this regard, transcriptomic analysis of liver tissues using next generation sequencing reinforces
the similarity of the BarNa model with the human disease. Pathway enrichment analysis illustrated
that BarNa animals shared a relevant number of central pathways involved in NASH pathophysiology,
including classical features of the disease (metabolism-related, inflammatory, and diabetes pathways)
and characteristics of cirrhotic livers (extracellular matrix and cancer-related pathways). Although
this pre-clinical model has dissimilarities at the transcriptomic level when compared to the human
disease, NASH animals have more common pathways with NAFLD patients than with NASH cirrhotic
patients, and on the other hand, the NASH-CH model shared more pathways with NASH patients
than with NAFLD, supporting the different applicability of the two BarNa models mentioned before.
In summary, the present study defines a pre-clinical model of moderate and advanced NASH that
mimics the broad spectrum of the human disease and shares a significant part of its gene signature.
We herein propose the BarNa model as a reliable tool for studying the pathophysiology of NASH and
for the development of new therapies.
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